Short Review on Treatment of Superficial Bladder Cancer (Ta, Tis, T1)

Phalguni Gupta
Additional contact information
Phalguni Gupta: Department of Radiotherapy, N R S Medical College, Kolkata India

Cancer Therapy & Oncology International Journal, 2019, vol. 14, issue 1, 1-2

Abstract: At presentation, 70% of patients with bladder cancer have superficial disease, out of which, approximately 15% to 20% will progress to stage T2 disease or greater over time. Following initial therapy, 50% to 70% of those presenting with Ta or T1 disease will have a recurrence. Low-grade tumors (grade I or II) and low-stage (Ta) disease tend to have a lower recurrence rate at about 50% and a 5% progression rate, whereas high-risk disease (grade III, T1 associated with CIS, and multifocal disease) has a 70% recurrence rate and a 30% progression rate to stage T2 disease or greater disease. Less than 5% of patients with superficial bladder cancer will develop metastatic disease without developing evidence of muscularis propria invasion (stage T2 disease or greater) of the primary lesion.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555876.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555876.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:14:y:2019:i:1:p:1-2

DOI: 10.19080/CTOIJ.2019.14.555876

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().